查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1403373

全基因組定序市場的全球市場預測（-2030）：按產品類型、工作流程、技術、應用、最終用戶和地區進行分析

Whole Genome Sequencing Market Forecasts to 2030 - Global Analysis By Product (Consumables, Instruments and Services), Type (Small Whole Genome Sequencing & Large Whole Genome Sequencing), Workflow, Technology, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

2023年全球全基因組定序市場規模為452.8億美元，預估2030年將達845.1億美元，預測期間內複合年成長率為13.5%。

全基因組定序 (WGS) 是一種用於確定生物體基因組完整 DNA 序列的綜合方法。基因組是DNA的完整集合，包括攜帶生物體發育、功能和維持的遺傳資訊的所有基因和非編碼區。全基因組定序在推動基因組學領域的研究和臨床應用方面發揮著重要作用。

根據美國疾病管制與預防中心的統計，美國大約每 707 名新生兒中就有 1 人患有唐氏症，即約 5,568 名嬰兒患有唐氏症。

遺傳病患病率上升

WGS 是識別與各種疾病相關的遺傳變異的強大工具。隨著遺傳病患疾病率的增加，對準確、全面的診斷方法的需求也隨之增加。全基因組定序可以對個體的整個基因組進行徹底檢查，從而深入了解疾病的遺傳基礎。 WGS 支持更了解潛在遺傳機制的研究工作。此外，人們對早期檢測和介入遺傳疾病管理重要性的認知不斷提高，也促進了對全基因組定序的需求。

在某些疾病狀態下臨床效用的局限性

某些疾病狀態，特別是複雜和多因素的疾病，可能具有尚未明確定義或易於解決的遺傳基礎。在某些情況下，特定基因組觀察與臨床結果之間的關聯尚未明確。缺乏可操作的資訊可能會限制全基因組定序的臨床效用，醫療保健提供者可能很難使用遺傳資料來指導治療決策。它也引發了人們對如何處理此類情況的道德擔憂。這阻礙了 WGS 融入臨床實踐。

腫瘤科招聘增加

全基因組定序可以對患者的基因組成進行全面分析，從而更好地了解癌症的分子促進因素。它有助於識別促進癌細胞生長的特定基因突變或變化。 WGS資料在腫瘤學研究中的使用有助於確定合適的臨床試驗候選者。隨著更多臨床證據的產生以及該技術變得更容易獲得和更具成本效益，WGS 在腫瘤學中的採用可能只會增加，從而推動市場擴張。

資料隱私和安全問題

基因組資料高度敏感，包含有關個體獨特遺傳傾向、疾病傾向和其他潛在個人特徵的資訊。詐欺存取基因組資料的風險引起了人們對濫用敏感資訊的擔憂。如果基因組資料落入壞人之手，它可以用於多種目的，包括身分盜竊、保險歧視和其他惡意活動。如果無法充分解決這些問題，可能會阻礙全基因組定序市場的成長。

COVID-19 的影響

COVID-19 大流行對全基因組定序市場產生了中性影響。這次大流行凸顯了遺傳學在理解和預防感染疾病方面的作用。世界各地的研究人員利用全基因組定序來研究 SARS-CoV-2 病毒的基因組成和演化歷史。這凸顯了遺傳學在個體化治療中的重要性。另一方面，市場暫時受到供應鏈中斷、研究目標變化等變數的影響。

精準醫療領域預計將在預測期內成為最大的領域

精準醫療領域估計是一個利潤豐厚的市場。精準醫療涉及根據每個患者的特徵做出醫療和保健決策。全基因組定序在精準醫學中發揮核心作用，提供個體整個基因組的全面分析。這有助於藥物選擇和給藥最佳化。此外，它還提供具有成本效益的治療、患者賦權和個體化護理計劃，這些計劃正在加速該細分市場的成長。

研究中心部門預計在預測期內複合年成長率最高。

由於廣泛研究領域的進步，研究中心領域預計在預測期內將出現最高的複合年成長率。 WGS 在研究中心提供了無數的應用和優勢，有助於對遺傳學、基因組學和各種生物過程的批判性理解。它也為了解疾病機制、確定潛在的治療標靶和開發個體化治療方法提供了重要資訊。

比最大的地區

由於研發活動投資的增加，預計亞太地區在預測期內將佔據最大的市場佔有率。亞太地區的生物技術和醫療領域正在經歷顯著成長。各國政府啟動了資助計畫和支持政策，鼓勵採用基因組技術進行研究和臨床應用。該地區人口的多樣化和常見疾病日益流行正在推動市場擴張。

複合年成長率最高的地區

由於政府財政支持的增加，預計北美在預測期內的複合年成長率最高。該地區擁有許多專注於基因組學和個人化醫療的大型生物技術和製藥公司。北美消費者有興趣了解他們的血統、某些健康狀況的傾向以及其他基因組資訊。此外，全基因組定序及其在癌症治療中的應用不斷湧現的技術創新正在加強該地區的市場趨勢。

免費客製化服務

訂閱此報告的客戶可以存取以下免費自訂選項之一：

  • 公司簡介
    • 其他市場公司的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域分割
    • 根據客戶興趣對主要國家的市場估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 調查來源
    • 主要調查來源
    • 二次調查來源
    • 先決條件

第3章市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 產品分析
  • 技術分析
  • 應用分析
  • 最終用戶分析
  • 新興市場
  • 新型冠狀病毒感染疾病（COVID-19）的影響

第4章波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章全球全基因組定序市場：分產品

  • 消耗品
  • 裝置
  • 服務

第6章全球全基因組定序市場：按類型

  • 小規模全基因組定序
  • 大規模全基因組定序

第7章全球全基因組定序市場：依工作流程

  • 資料分析
  • 順序
  • 前序

第8章全球全基因組定序市場：依技術分類

  • Sanger序列
  • 微陣列
  • 聚合酶鍊式反應
  • 下一代定序
  • 其他技術

第9章全球全基因組定序市場：依應用分類

  • 藥物研發發現與開發
  • 診斷
  • 精準醫療
  • 其他用途

第10章 全球全基因組定序市場：依最終用戶分類

  • 學術機構
  • 醫院和診所
  • 研究中心
  • 製藥和生物技術公司
  • 其他最終用戶

第11章全球全基因體定序市場：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲

第12章 主要進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第13章 公司簡介

  • Siemens Healthineers
  • Thermo Fisher Scientific Inc
  • F. Hoffmann-La Roche Ltd
  • Danaher Corporation
  • Agilent Technologies Inc
  • Illumina Inc
  • Complete Genomics
  • QIAGEN NV
  • GeneDx
  • Merck KGaA
  • Abbott
  • Eurofins Scientific
  • Oxford Nanopore Technologies
  • Bio-Rad Laboratories, Inc
  • Macrogens Inc
Product Code: SMRC24598

According to Stratistics MRC, the Global Whole Genome Sequencing Market is accounted for $45.28 billion in 2023 and is expected to reach $84.51 billion by 2030 growing at a CAGR of 13.5% during the forecast period. Whole Genome Sequencing (WGS) is a comprehensive method used to determine the complete DNA sequence of an organism's genome. The genome is the complete set of DNA, including all of the genes and non-coding regions that carry the genetic information for the development, functioning, and maintenance of an organism. Whole genome sequencing plays a critical role in advancing both research and clinical applications in the field of genomics.

According to the Centers for Disease Control and Prevention statistics, around 1 in every 707 newborn children in the U.S. suffer from Down syndrome, which accounts for approximately 5,568 children in the U.S.

Market Dynamics:

Driver:

Rising prevalence of genetic disorders

WGS is a powerful tool for identifying genetic variations associated with various disorders. As the prevalence of genetic disorders increases, there is a growing need for accurate and comprehensive diagnostic methods. WGS allows for a thorough examination of an individual's entire genome, providing insights into the genetic basis of diseases. It fuels the research efforts to better understand the underlying genetic mechanisms. Further, the rising awareness of the importance of early detection and intervention in managing genetic disorders contributes to the demand for WGS.

Restraint:

Limited clinical utility in certain conditions

In certain medical conditions, especially complex and multifactorial diseases, the genetic basis may not be well-defined or easily actionable. In some cases, the relevance of specific genomic findings to clinical outcomes may not be well-established. This lack of actionable information can limit the clinical utility of WGS, as healthcare providers may struggle to use the genetic data to inform treatment decisions. It also raises ethical concerns about how to handle such conditions. Thereby, it hinders the integration of WGS into clinical practice.

Opportunity:

Increasing adoption in oncology

Whole genome sequencing enables a comprehensive analysis of a patient's genetic makeup, allowing for a better understanding of the molecular drivers of cancer. It helps to identify specific genetic mutations and alterations that drive the growth of cancer cells. The use of WGS data in oncology research is instrumental in the identification of suitable candidates for clinical trials. As more clinical evidence is generated, and the technology becomes more accessible and cost-effective, the adoption of WGS in oncology is likely to continue its upward trajectory, driving market expansion.

Threat:

Data privacy & security concerns

Genomic data is highly sensitive and contains information about an individual's unique genetic makeup, predispositions to diseases, and potentially other personal traits. The risk of unauthorized access to genomic data raises concerns about the misuse of sensitive information. If genomic data falls into the wrong hands, it could be exploited for various purposes, including identity theft, insurance discrimination, or other malicious activities. Failure to adequately address these concerns can impede the growth of the whole genome sequencing market.

COVID-19 Impact

The covid pandemic had a neutral effect on the whole genome sequencing market. The pandemic highlighted the role that genetics plays in comprehending and preventing infectious illnesses. Whole genome sequencing has been used by researchers all around the world to examine the genetic composition and evolutionary history of the SARS-CoV-2 virus. This lightened the significance of genetics in personalized treatment. On the other hand, the market was momentarily impacted by variables including the interruption of supply networks and changes in research objectives.

The precision medicine segment is expected to be the largest during the forecast period

The precision medicine segment is estimated to have a lucrative. Precision medicine involves tailoring medical treatment and healthcare decisions to the individual characteristics of each patient. Whole genome sequencing plays a central role in precision medicine, providing a comprehensive analysis of an individual's entire genome. It helps to optimize drug selection and dosage. Additionally, it offers cost effective treatments, patient empowerment and personalized care plans which accelerates the segment growth.

The research centers segment is expected to have the highest CAGR during the forecast period

The research centers segment is anticipated to witness the highest CAGR growth during the forecast period, due to the advancements in a wide range of research fields. WGS offers a myriad of uses and benefits in research centers, contributing to the significant understanding of genetics, genomics, and various biological processes. It also provides critical information for understanding disease mechanisms, identifying potential therapeutic targets, and developing personalized treatment approaches.

Region with largest share:

Asia Pacific is projected to hold the largest market share during the forecast period owing to the growing investment in R&D activities. The Asia-Pacific region has experienced substantial growth in the biotechnology and healthcare sectors. Governments have initiated funding programs and supportive policies to encourage the adoption of genomic technologies for research and clinical applications. The region's diverse population along with growing generic disorders is boosting the market's expansion.

Region with highest CAGR:

North America is projected to have the highest CAGR over the forecast period, owing to the rising government funding. The region hosts numerous leading biotechnology & pharmaceutical companies focused on genomics and personalized medicine. Consumers in North America have shown interest in learning about their ancestry, predisposition to certain health conditions, and other genomic information. Further, the rising innovation in whole genome sequencing and its application in cancer treatments are thereby augmenting the regional market trends.

Key players in the market:

Some of the key players profiled in the Whole Genome Sequencing Market include Siemens Healthineers, Thermo Fisher Scientific Inc, F. Hoffmann-La Roche Ltd, Danaher Corporation, Agilent Technologies Inc, Illumina Inc, Complete Genomics, QIAGEN N.V., GeneDx, Merck KGaA, Abbott, Eurofins Scientific, Oxford Nanopore Technologies, Bio-Rad Laboratories, Inc and Macrogens Inc.

Key Developments:

In October 2023, Oxford Nanopore Technologies and Fabric Genomics collaborated to launch an integrated whole-genome sequencing solution to advance the future of paediatric patient care. The joint solution, which will be commercially available for deployment in CLIA/CAP labs, will support use of nanopore sequencing in neonatal/pediatric intensive care units.

In October 2023, Complete Genomics, a pioneering genomic sequencing company, launched its DNBSEQ-T20x2* product, which reduced the cost of whole genome sequencing to less than $100 per 30X WGS.

In August 2023, GeneDx and PacBio announced research collaboration with the University of Washington to study the capabilities of HiFi long-read whole genome sequencing (WGS) to increase diagnostic rates in pediatric patients with genetic conditions.

Products Covered:

  • Consumables
  • Instruments
  • Services

Types Covered:

  • Small Whole Genome Sequencing
  • Large Whole Genome Sequencing

Workflows Covered:

  • Data Analysis
  • Sequencing
  • Pre-Sequencing

Technologies Covered:

  • Sanger Sequencing
  • Microarray
  • Polymerase Chain Reaction
  • Next Generation Sequencing
  • Other Technologies

Applications Covered:

  • Drug Discovery & Development
  • Diagnostics
  • Precision Medicine
  • Other Applications

End Users Covered:

  • Academic Institutes
  • Hospitals & Clinics
  • Research Centers
  • Pharmaceutical & Biotechnology Companies
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Technology Analysis
  • 3.8 Application Analysis
  • 3.9 End User Analysis
  • 3.10 Emerging Markets
  • 3.11 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Whole Genome Sequencing Market, By Product

  • 5.1 Introduction
  • 5.2 Consumables
  • 5.3 Instruments
  • 5.4 Services

6 Global Whole Genome Sequencing Market, By Type

  • 6.1 Introduction
  • 6.2 Small Whole Genome Sequencing
  • 6.3 Large Whole Genome Sequencing

7 Global Whole Genome Sequencing Market, By Workflow

  • 7.1 Introduction
  • 7.2 Data Analysis
  • 7.3 Sequencing
  • 7.4 Pre-Sequencing

8 Global Whole Genome Sequencing Market, By Technology

  • 8.1 Introduction
  • 8.2 Sanger Sequencing
  • 8.3 Microarray
  • 8.4 Polymerase Chain Reaction
  • 8.5 Next Generation Sequencing
  • 8.6 Other Technologies

9 Global Whole Genome Sequencing Market, By Application

  • 9.1 Introduction
  • 9.2 Drug Discovery & Development
  • 9.3 Diagnostics
  • 9.4 Precision Medicine
  • 9.5 Other Applications

10 Global Whole Genome Sequencing Market, By End User

  • 10.1 Introduction
  • 10.2 Academic Institutes
  • 10.3 Hospitals & Clinics
  • 10.4 Research Centers
  • 10.5 Pharmaceutical & Biotechnology Companies
  • 10.6 Other End Users

11 Global Whole Genome Sequencing Market, By Geography

  • 11.1 Introduction
  • 11.2 North America
    • 11.2.1 US
    • 11.2.2 Canada
    • 11.2.3 Mexico
  • 11.3 Europe
    • 11.3.1 Germany
    • 11.3.2 UK
    • 11.3.3 Italy
    • 11.3.4 France
    • 11.3.5 Spain
    • 11.3.6 Rest of Europe
  • 11.4 Asia Pacific
    • 11.4.1 Japan
    • 11.4.2 China
    • 11.4.3 India
    • 11.4.4 Australia
    • 11.4.5 New Zealand
    • 11.4.6 South Korea
    • 11.4.7 Rest of Asia Pacific
  • 11.5 South America
    • 11.5.1 Argentina
    • 11.5.2 Brazil
    • 11.5.3 Chile
    • 11.5.4 Rest of South America
  • 11.6 Middle East & Africa
    • 11.6.1 Saudi Arabia
    • 11.6.2 UAE
    • 11.6.3 Qatar
    • 11.6.4 South Africa
    • 11.6.5 Rest of Middle East & Africa

12 Key Developments

  • 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 12.2 Acquisitions & Mergers
  • 12.3 New Product Launch
  • 12.4 Expansions
  • 12.5 Other Key Strategies

13 Company Profiling

  • 13.1 Siemens Healthineers
  • 13.2 Thermo Fisher Scientific Inc
  • 13.3 F. Hoffmann-La Roche Ltd
  • 13.4 Danaher Corporation
  • 13.5 Agilent Technologies Inc
  • 13.6 Illumina Inc
  • 13.7 Complete Genomics
  • 13.8 QIAGEN N.V.
  • 13.9 GeneDx
  • 13.10 Merck KGaA
  • 13.11 Abbott
  • 13.12 Eurofins Scientific
  • 13.13 Oxford Nanopore Technologies
  • 13.14 Bio-Rad Laboratories, Inc
  • 13.15 Macrogens Inc

List of Tables

  • Table 1 Global Whole Genome Sequencing Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Whole Genome Sequencing Market Outlook, By Product (2021-2030) ($MN)
  • Table 3 Global Whole Genome Sequencing Market Outlook, By Consumables (2021-2030) ($MN)
  • Table 4 Global Whole Genome Sequencing Market Outlook, By Instruments (2021-2030) ($MN)
  • Table 5 Global Whole Genome Sequencing Market Outlook, By Services (2021-2030) ($MN)
  • Table 6 Global Whole Genome Sequencing Market Outlook, By Type (2021-2030) ($MN)
  • Table 7 Global Whole Genome Sequencing Market Outlook, By Small Whole Genome Sequencing (2021-2030) ($MN)
  • Table 8 Global Whole Genome Sequencing Market Outlook, By Large Whole Genome Sequencing (2021-2030) ($MN)
  • Table 9 Global Whole Genome Sequencing Market Outlook, By Workflow (2021-2030) ($MN)
  • Table 10 Global Whole Genome Sequencing Market Outlook, By Data Analysis (2021-2030) ($MN)
  • Table 11 Global Whole Genome Sequencing Market Outlook, By Sequencing (2021-2030) ($MN)
  • Table 12 Global Whole Genome Sequencing Market Outlook, By Pre-Sequencing (2021-2030) ($MN)
  • Table 13 Global Whole Genome Sequencing Market Outlook, By Technology (2021-2030) ($MN)
  • Table 14 Global Whole Genome Sequencing Market Outlook, By Sanger Sequencing (2021-2030) ($MN)
  • Table 15 Global Whole Genome Sequencing Market Outlook, By Microarray (2021-2030) ($MN)
  • Table 16 Global Whole Genome Sequencing Market Outlook, By Polymerase Chain Reaction (2021-2030) ($MN)
  • Table 17 Global Whole Genome Sequencing Market Outlook, By Next Generation Sequencing (2021-2030) ($MN)
  • Table 18 Global Whole Genome Sequencing Market Outlook, By Other Technologies (2021-2030) ($MN)
  • Table 19 Global Whole Genome Sequencing Market Outlook, By Application (2021-2030) ($MN)
  • Table 20 Global Whole Genome Sequencing Market Outlook, By Drug Discovery & Development (2021-2030) ($MN)
  • Table 21 Global Whole Genome Sequencing Market Outlook, By Diagnostics (2021-2030) ($MN)
  • Table 22 Global Whole Genome Sequencing Market Outlook, By Precision Medicine (2021-2030) ($MN)
  • Table 23 Global Whole Genome Sequencing Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 24 Global Whole Genome Sequencing Market Outlook, By End User (2021-2030) ($MN)
  • Table 25 Global Whole Genome Sequencing Market Outlook, By Academic Institutes (2021-2030) ($MN)
  • Table 26 Global Whole Genome Sequencing Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
  • Table 27 Global Whole Genome Sequencing Market Outlook, By Research Centers (2021-2030) ($MN)
  • Table 28 Global Whole Genome Sequencing Market Outlook, By Pharmaceutical & Biotechnology Companies (2021-2030) ($MN)
  • Table 29 Global Whole Genome Sequencing Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.